MX366164B - Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. - Google Patents

Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Info

Publication number
MX366164B
MX366164B MX2017013491A MX2017013491A MX366164B MX 366164 B MX366164 B MX 366164B MX 2017013491 A MX2017013491 A MX 2017013491A MX 2017013491 A MX2017013491 A MX 2017013491A MX 366164 B MX366164 B MX 366164B
Authority
MX
Mexico
Prior art keywords
prostate cancer
test
gene expression
expression profile
determining prognosis
Prior art date
Application number
MX2017013491A
Other languages
English (en)
Inventor
J Pelham Robert
Crager Michael
Shak Steve
Lee Mark
Novotny William
Cherbavaz Diana
L Millward Carl
Knezevic Dejan
Maddala Tara
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX366164B publication Critical patent/MX366164B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)

Abstract

La presente invención se refiere a ensayos moleculares basados en algoritmo que implica en la medición de los niveles de expresión de los genes, o sus genes co-expresados, de una muestra biológica obtenida de un paciente con cáncer de próstata. Los genes se pueden agrupar en subconjuntos de genes funcionales para calcular un registro cuantitativo útil para predecir una probabilidad de un resultado clínico para un paciente con cáncer de próstata.
MX2017013491A 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. MX366164B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593106P 2012-01-31 2012-01-31
US201261672679P 2012-07-17 2012-07-17
US201261713734P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
MX366164B true MX366164B (es) 2019-07-01

Family

ID=48870540

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017013491A MX366164B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2014009283A MX351626B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019007814A MX2019007814A (es) 2012-01-31 2014-07-31 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014009283A MX351626B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019007814A MX2019007814A (es) 2012-01-31 2014-07-31 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Country Status (14)

Country Link
US (3) US8725426B2 (es)
EP (3) EP2809812A4 (es)
JP (3) JP6351112B2 (es)
AU (3) AU2013215448B2 (es)
CA (1) CA2863040C (es)
CO (1) CO7051010A2 (es)
DK (1) DK3179393T3 (es)
ES (1) ES2812105T3 (es)
HK (1) HK1201881A1 (es)
IL (3) IL233709A (es)
MX (3) MX366164B (es)
NZ (2) NZ722902A (es)
SG (3) SG10201605210PA (es)
WO (1) WO2013116144A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
EP3084426B1 (en) * 2013-12-18 2020-04-15 Pacific Biosciences Of California, Inc. Iterative clustering of sequence reads for error correction
CN103695560B (zh) * 2014-01-09 2016-09-14 上海交通大学医学院附属瑞金医院 Ppp1r12a基因在结直肠癌化疗疗效判断和检测试剂盒中的应用
CA2935720A1 (en) * 2014-01-16 2015-07-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
US20170016903A1 (en) * 2014-02-28 2017-01-19 The Johns Hopkins University Genes encoding secreted proteins which identify clinically significant prostate cancer
WO2016062891A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION
JP7065609B6 (ja) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
CN108064380A (zh) 2014-10-24 2018-05-22 皇家飞利浦有限公司 使用多种细胞信号传导途径活性的医学预后和治疗反应的预测
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
US11827938B2 (en) * 2015-05-29 2023-11-28 Koninklijke Philips N.V. Methods of prostate cancer prognosis
WO2016193109A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis
US20180188258A1 (en) * 2015-07-01 2018-07-05 Keio University Marker for heterogeneity of cancer tissue, and use thereof
EP3334837B1 (en) 2015-08-14 2020-12-16 Koninklijke Philips N.V. Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017127696A1 (en) * 2016-01-20 2017-07-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
DK3270163T3 (en) * 2016-07-15 2018-11-19 Proteomedix Ag PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11586674B2 (en) * 2016-12-28 2023-02-21 Khalifa University of Science and Technology Methods and systems for searching
JP7239477B2 (ja) * 2017-02-13 2023-03-14 ジェノミック ヘルス， インコーポレイテッド 前立腺がんにおける後期臨床エンドポイントを評価するためのアルゴリズムおよび方法
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019082118A1 (en) * 2017-10-27 2019-05-02 King Abdullah University Of Science And Technology GRAPHIC BASED CONSTANT COLUMN DOUBLE CLASSIFICATION DEVICE AND METHOD FOR MINIMIZING GROWTH PHENOTYPE DATA
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502280A1 (en) * 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
CA3089406A1 (en) * 2018-01-25 2019-08-01 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
EP3755816A1 (en) * 2018-02-22 2020-12-30 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN109001467A (zh) * 2018-07-20 2018-12-14 贵州省人民医院 一种用于前列腺癌的基因联合预后检测试剂及其制备方法
GB201816820D0 (en) * 2018-10-16 2018-11-28 Univ York Diagnostic method
WO2020092808A1 (en) 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
AU2020329191A1 (en) 2019-08-12 2022-03-31 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
EP3901288A1 (en) * 2020-04-20 2021-10-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-gene expression assay for prostate carcinoma

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
JP2003528564A (ja) 1998-06-06 2003-09-30 ジェノスティック ファーマ リミテッド 遺伝的プロファイリングに使用するプローブ
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
JP2003519491A (ja) 2000-01-13 2003-06-24 ジェネンテック・インコーポレーテッド 新規なｓｔｒａ６ポリペプチド
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
AU2002251844A1 (en) 2001-02-02 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003040404A1 (en) 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU2002357747A1 (en) 2001-12-10 2003-06-23 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
WO2003076610A2 (fr) 2002-03-14 2003-09-18 Exonhit Therapeutics Sa Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
AUPS187002A0 (en) 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
EP1552293A4 (en) 2002-09-10 2006-12-06 Guennadi V Glinskii METHOD FOR SEGREGATION OF GENES AND CLASSIFICATION OF BIOLOGICAL SAMPLES
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
WO2005100606A2 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005113816A2 (en) 2004-05-07 2005-12-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
EP1766091A4 (en) 2004-05-27 2009-03-18 Vertex Pharma BIOMARKER FOR MONITORING THE INHIBITION OF THE IMPDH PATH
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
EP1784511A4 (en) 2004-08-13 2009-03-11 Millennium Pharm Inc GENES, COMPOSITIONS, KITS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF PROSTATE CANCER
WO2006091776A2 (en) 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
JP2008536488A (ja) 2005-03-16 2008-09-11 シドニー キンメル キャンサー センター 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007028146A2 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
DE06814528T1 (de) 2005-09-12 2012-01-05 The Regent Of The University Of Michigan Wiederkehrende genfusionen bei prostatakrebs
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
ES2300176B1 (es) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
EP2029020A4 (en) 2006-06-22 2010-04-21 Wisconsin Alumni Res Found USE OF STROMA COLLAGEN IN THE DIAGNOSIS AND CHARACTERIZATION OF BREAST CANCER
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2008061104A2 (en) * 2006-11-13 2008-05-22 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
WO2008115419A2 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8835480B2 (en) * 2007-04-23 2014-09-16 California Institute Of Technology Inhibitors for steroid response elements and related methods
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
US20110265197A1 (en) 2008-07-16 2011-10-27 Dana-Farber Cancer Institute, Inc. Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
WO2010056993A2 (en) 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
CA2749103A1 (en) 2009-01-07 2010-07-15 Steve Stone Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
CN102473202B (zh) 2009-07-08 2015-11-25 环球创新网络公司 用于预测药物在患者中的疗效的方法
ES2735993T3 (es) 2009-11-23 2019-12-23 Genomic Health Inc Métodos para predecir el resultado clínico del cáncer
NZ617003A (en) 2010-01-11 2015-04-24 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer

Also Published As

Publication number Publication date
JP2015511814A (ja) 2015-04-23
SG10201912312YA (en) 2020-02-27
JP2019013255A (ja) 2019-01-31
IL262648A (en) 2018-12-31
HK1201881A1 (en) 2015-09-11
MX2019007814A (es) 2019-09-05
US20140303002A1 (en) 2014-10-09
JP6351112B2 (ja) 2018-07-04
EP2809812A1 (en) 2014-12-10
EP3179393B1 (en) 2020-07-08
MX351626B (es) 2017-10-23
ES2812105T3 (es) 2021-03-16
AU2013215448B2 (en) 2018-01-04
CA2863040A1 (en) 2013-08-08
US8725426B2 (en) 2014-05-13
NZ722902A (en) 2017-12-22
CO7051010A2 (es) 2014-09-10
AU2018201688A1 (en) 2018-04-05
IL262648B (en) 2020-07-30
US20130196321A1 (en) 2013-08-01
EP3179393A2 (en) 2017-06-14
IL254255B (en) 2018-11-29
EP2809812A4 (en) 2016-01-27
AU2018201688B2 (en) 2020-02-27
IL233709A (en) 2017-09-28
EP3179393A3 (en) 2017-09-13
JP6908571B2 (ja) 2021-07-28
SG11201404390WA (en) 2014-08-28
AU2020202164B2 (en) 2022-02-10
DK3179393T3 (da) 2020-07-27
IL254255A0 (en) 2017-10-31
NZ627887A (en) 2016-08-26
CA2863040C (en) 2022-04-19
EP3739595A2 (en) 2020-11-18
AU2013215448A1 (en) 2014-08-21
US11011252B1 (en) 2021-05-18
EP3739595A3 (en) 2021-01-27
SG10201605210PA (en) 2016-08-30
WO2013116144A1 (en) 2013-08-08
AU2020202164A1 (en) 2020-04-16
IL233709A0 (en) 2014-09-30
MX2014009283A (es) 2014-09-11
JP2017113008A (ja) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
BR112014025269A2 (pt) método para o prognóstico e tratamento de metástase de câncer
NZ599194A (en) Methods to predict clinical outcome of cancer
NZ723570A (en) Compositions and methods for quantifying a nucleic acid sequence in a sample
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.
WO2013190468A3 (en) Computer-based predictor for prostate cancer
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.
WO2013172934A8 (en) Integrin genetic variants and stage-specific tumor recurrence in patients with stage ii and iii colon cancer
WO2011133500A3 (en) Detection and analysis of epigenetic and genetic changes in tumor tissue
UA106708U (uk) Спосіб прогнозування зрощення перелому
NZ610474A (en) Methods to predict clinical outcome of cancer
RU2013120609A (ru) Способ косвенного определения чувствительности клеток рака легкого к цисплатину на основании уровней экспрессии маркерных генов и набор для его осуществления